Management Of Malignant Hyperthermia Update 2019

Malignant hyperthermia (MH) is defined as on abnormal response to halogenated anaesthetic agents and/or depolarising curare in individuals with a genetic abnormality affecting skeletal striated muscle. The professional practice recommendations for the management of malignant hyperthermia include the following: 1- Screening of patients at risk of malignant hyperthermia in anaesthesia consultation. 2- How to perform the diagnosis of malignant hyperthermia susceptibility? 3- How to perform anaesthesia in a patient at risk of malignant hyperthermia? 4- How to summarise the diagnosis and treatment of malignant hyperthermia? 5- What to do after a malignant hyperthermia crisis. Appendices list the French diagnostic centres for malignant hyperthermia, details on the genetic analysis performed in this context and a poster of recommendations with a side on the diagnosis and treatment of the crisis, and a side on the reconstitution of dontrolene.